Select publications
Arends R et al. Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients. Proc ASCO 2005;Abstract 3089.
Chu E. Panitumumab: A new anti-EGFR antibody for the treatment of advanced colorectal cancer. Clin Colorectal Cancer 2006;6(1):13. No abstract available
Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7(10):2958-70. Abstract
Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45. Abstract
Giantonio BJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO 2005;Abstract 2.
Gibson TB et al. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6(1):29-31. Abstract
Gould P. Monoclonal antibody aids colorectal-cancer treatment. Lancet Oncol 2006;7(5):370. No abstract available
Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 2005;23(15):3311-3.No abstract available
Hochster HS et al. Results of the TREE-2 cohort: Safety, tolerability, and efficacy of bevacizumab added to three oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer. Proc ASCO GI Cancers Symposium 2006a;Abstract 244.
Hochster HS et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-study. Proc ASCO 2006b;Abstract 3510.
Malik I et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proc ASCO 2005;Abstract 3520.
Peeters M et al. A Phase 3, Multicenter, Randomized Controlled Trial (RCT) of panitumumab plus Best Supportive Care (BSC) vs BSC alone in patients (pts) with Metastatic Colorectal Cancer (mCRC). Proc AACR 2006;Abstract CP-1.
Roskos L et al. Low pharmacokinetic variability facilitates optimal dosing of ABX-EGF in cancer patients. Proc ASCO 2002;Abstract 362.
Saltz LB et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO GI Cancers Symposium 2005;Abstract 169b.
Saltz L et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc ASCO 2001;Abstract 7.
Snyder LC et al. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer 2005;(5 Suppl 2):71-80. Abstract
Terstriep S, Grothey A. First- and second-line therapy of metastatic colorectal cancer. Expert Rev Anticancer Ther 2006;6(6):921-30. Abstract
Thomas SM, Gandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004;30(3):255-68. Abstract
Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 2005;(5 Suppl 1):19-27. Abstract
Venook A et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc ASCO 2006;Abstract 3509.
Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;5(5):363-7. Abstract
Weiner LM et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. Proc ASCO 2005;Abstract 3059.
